Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion

Neurooncol Adv. 2024 May 11;6(1):vdae077. doi: 10.1093/noajnl/vdae077. eCollection 2024 Jan-Dec.

Giulia Cerretti^{1

2}, Marta Padovan^{1

2}, Angela Guerriero³, Marta Maccari^{2

4}, Alberto Bosio^{2

4}, Mario Caccese², Eugenia Cella⁵, Giovanna Pintacuda⁶, Giovanni Librizzi⁷, Giuseppe Lombardi²

¹ PhD course in Clinical and Experimental Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
² Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
³ Surgical Pathology Unit, University Hospital of Padova, Padova, Italy.
⁴ School of Specialization in Medical Oncology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
⁵ Oncology 2, IRCCS Ospedale San Martino, Genova, Italy.
⁶ Radiology Unit, Veneto Institute of Oncology IOV - IRCCS.
⁷ Department of Neuroscience, Azienda Ospedale-Università di Padova, Padova, Italy.

No abstract available

Keywords: ROS1; complete response; entrectinib; glioblastoma; targeted therapy.